abstract_id,endpoint_name,endpoint_decision_rule,endpoint_type,endpoint_id
3764,safety,No increase in the incidence of adverse events and no grade 3/4 treatment-related adverse events.,secondary,293
3392,overall response rate (ORR),An ORR ≥ 60% was considered worthy of further study.,primary,168
3065,progression free survival (PFS) in randomized patients,Statistical significance is achieved if p < 0.05.,primary,148
3065,overall survival,Statistical significance is achieved if p < 0.05.,not_stated,147
17,"event-free survival (EFS = absence of progression, recurrence, 2 consecutive CA19.9 increases ≥20% separated by ≥ 4 weeks, unresectability, intra-operative metastasis, death)",With 173 events (260 pts) the study has a power of 80% to demonstrate a statistically significant difference at 5% two sided stratified logrank test under the alternative hypothesis of HR=0.65.,primary,325
3620,ORR by ICR,The observed ORR must be greater than a pre-specified threshold for success.,primary,176
97,dose-limiting toxicity (DLT),3+3 design,primary,16
97,determination of the maximum tolerated dose (MTD),3+3 design,primary,15
2943,CRR at 3 mo,"Demonstrate a 53% CRR for the combination, based on a Pem historical control of 41% (one-sided alpha 0.05, power 82%).",primary,142
1469,HHV-8 DNA decline,p < 0.05 for statistical significance,exploratory,264
1469,HIV-VL changes,No significant change in HIV-VL,exploratory,265
1469,CD4 changes,No significant change in CD4 count,exploratory,263
1469,T-regs increase,p < 0.05 for statistical significance,exploratory,267
1469,macrophages decrease,p < 0.05 for statistical significance,exploratory,268
1469,"Rise in NK, CD4, and CD8 naïve cells",p < 0.05 for statistical significance,exploratory,266
3720,major pathologic response (MPR),rejecting the null hypothesis if 10 or more responses (37%) are observed in 27 pts,primary,192
4375,progression-free survival (PFS) from randomization,p < 0.05 for statistical significance,primary,229
327,OS in patients with irAE vs without,Superiority vs. null hypothesis of no difference (p < 0.05),exploratory,21
327,PFS in patients with PDL1 CPS ≥10 vs lower,Superiority vs. null hypothesis of no difference (p < 0.05),exploratory,22
327,OS in patients with high TILs vs low,Superiority vs. null hypothesis of no difference (p < 0.05),exploratory,20
327,Association of DNA repair pathway activation with PFS,Superiority vs. null hypothesis of no association (p < 0.05),exploratory,17
327,Association of MYC target pathway activation with PFS,Superiority vs. null hypothesis of no association (p < 0.05),exploratory,19
327,Association of KRAS signaling activation with OS,Superiority vs. null hypothesis of no association (p < 0.05),exploratory,18
65,disease free survival (DFS) (T+OFS vs T in SOFT),Superiority (95% CI for HR excludes 1),primary,154
65,invasive breast cancer-free interval (BCFI) (T+OFS vs T in SOFT),Superiority (95% CI for HR excludes 1),secondary,157
65,disease free survival (DFS) (E+OFS vs T in SOFT),Superiority (95% CI for HR excludes 1),primary,152
65,overall survival (OS) (T+OFS vs T in SOFT),Superiority (95% CI for HR excludes 1),secondary,160
65,overall survival (OS) (E+OFS vs T in SOFT),Superiority (95% CI for HR excludes 1),secondary,158
65,disease free survival (DFS) (E+OFS vs T+OFS in TEXT+SOFT),Superiority (95% CI for HR excludes 1),primary,153
65,invasive breast cancer-free interval (BCFI) (E+OFS vs T+OFS in TEXT+SOFT),Superiority (p < 0.05),secondary,156
65,distant recurrence free interval (DRFI) (E+OFS vs T+OFS in TEXT+SOFT),Superiority (p < 0.05),secondary,155
65,overall survival (OS) (E+OFS vs T+OFS in TEXT+SOFT),Superiority (95% CI for HR excludes 1),secondary,159
1118,1-year progression-free survival (PFS) rate from the initiation of chemoradiotherapy with TMZ,"threshold 1-year PFS, 27%",primary,63
450,analysis of adverse events and dose-limiting toxicity (DLT),Determine if the combination has an acceptable safety profile and identify any dose-limiting toxicities.,primary,261
2641,recurrence-free survival (RFS),p < 0.05 for statistical significance,primary,281
1895,disease control rate (DCR),the study would be considered positive if 4 or more pts achieve disease control among 25 pts in the second stage,primary,107
1608,dose-limiting toxicity,Absence of dose-limiting toxicity at a given dose level.,primary,93
1608,treatment related adverse events (TRAEs),Acceptable safety and tolerability profile.,secondary,94
2329,dose-limiting toxicities (DLTs) within the first 28 days,"Determine the recommended phase 2 dose (RP2D) of S for dose expansion in phase 2 part based on dose-limiting toxicities (DLTs) within the first 28 days in a ""3+3"" algorithm.",primary,123
2329,ORR in patients with DDR-related mutations vs without,p < 0.05 for statistical significance,exploratory,120
2329,PFS in patients with DDR-related mutations vs without,p < 0.05 for statistical significance,exploratory,122
2329,OS in patients with DDR-related mutations vs without,p < 0.05 for statistical significance,exploratory,121
1698,objective response rate (ORR) by independent central review (ICR) in Group A,"The primary endpoint is met if the p-value from a one-sided test is < 0.05, testing the null hypothesis that the true objective response rate is ≤ 5%.",primary,99
1698,objective response rate (ORR) by independent central review (ICR) in Group B,"The primary endpoint is met if the p-value from a one-sided test is < 0.05, testing the null hypothesis that the true objective response rate is ≤ 5%.",primary,100
1698,objective response rate (ORR) by independent central review (ICR) in Group C,"The primary endpoint is met if the p-value from a one-sided test is < 0.05, testing the null hypothesis that the true objective response rate is ≤ 5%.",primary,101
3719,Pain scores,P-value < 0.05 was considered significant.,not_stated,290
3719,Swallowing difficulties,P-value < 0.05 was considered significant.,not_stated,292
3719,Speech-related challenges,P-value < 0.05 was considered significant.,not_stated,291
3719,Fatigue scores,P-value < 0.05 was considered significant.,not_stated,288
3719,Emotional well-being,P-value < 0.05 was considered significant.,not_stated,287
3719,Overall HRQoL scores,P-value < 0.05 was considered significant.,not_stated,289
1825,etoposide exposure,Absence of major changes in etoposide exposure.,not_stated,271
1825,Debio 0123 PK,Consistency with previously reported monotherapy PK data.,not_stated,270
2747,toxicity,No new and unexpected (S)AEs.,secondary,282
1049,Feasibility of a decentralized trial assessing neurocognitive outcomes,Feasibility is demonstrated by high completion rates of questionnaires and cognitive evaluations.,exploratory,262
14,IRC-assessed PFS,non-inferiority margin HR≤1.09,primary,311
1152,safety and tolerability,Assess safety and tolerability according to NCI-CTCAE v.5.0.,primary,65
1618,maximum tolerated dose,"Dose-limiting toxicities assessed during Cycle 1 based on a ""3+3 design"".",primary,96
4795,ORR,the trial will be discontinued at this stage if fewer than 2 Pts demonstrate a response,primary,296
4390,major pathological response (MPR),"Simon’s design (P0=20%, P1=40%)",primary,230
3905,complete hematological remission,Achieve complete hematological remission.,not_stated,197
3905,molecular remission,Achieve molecular remission.,not_stated,198
3905,prolonged neutropenia (> 28 days),No occurrence of prolonged neutropenia (> 28 days).,not_stated,199
3905,severe mucositis (Grade 3 or 4),No occurrence of severe mucositis (Grade 3 or 4).,not_stated,200
3905,cardiotoxicity,No occurrence of cardiotoxicity.,not_stated,196
3905,DIC,No occurrence of DIC.,not_stated,195
1325,maximum tolerated dose (MTD),Determine the maximum tolerated dose (MTD).,primary,89
4540,major pathologic response (MPR),The study would be stopped early if ≤one of eight patients achieving MPR at Stage 1.,primary,295
4719,superiority of Afa over Osi at 3-year survival rate,Superiority of Afa over Osi at 3-year survival rate,co-primary,248
4719,exploration of immunological biomarkers for treatment outcomes,Exploration of immunological biomarkers for treatment outcomes,co-primary,247
4719,Progression-free survival (PFS),p < 0.05 for statistical significance,not_stated,246
4719,Overall survival (OS),p < 0.05 for statistical significance,not_stated,243
4719,PFS in Osi-treated pts with high Th7R,p < 0.05 for statistical significance,exploratory,245
4719,OS in Osi-treated pts with high Th7R,p < 0.05 for statistical significance,exploratory,242
4719,PFS in Osi-treated pts with high Th2,p < 0.05 for statistical significance,exploratory,244
4719,OS in Osi-treated pts with high Th2,p < 0.05 for statistical significance,exploratory,241
1058,objective response rate (ORR; partial plus complete) per RANO (cohort A),ORR > 28%,primary,59
1372,tolerability,Absence of Dose-Limiting Toxicities (DLTs),not_stated,257
1372,Dose-Limiting Toxicities (DLTs),Absence of DLTs in a given cohort.,not_stated,256
4334,"incidence of adverse events (AEs), including dose-limiting toxicities (DLTs)",Dose escalation was conducted using a modified toxicity probability interval method.,primary,221
5327,12-month progression-free survival (PFS) rates for patients with refractory and progressive disease,p < 0.05 for statistical significance,not_stated,307
5327,12-month overall survival (OS) rates for patients with refractory and progressive disease,p < 0.05 for statistical significance,not_stated,306
5327,12-month PFS rate for patients who received sintilimab therapy compared to those who did not,p < 0.05 for statistical significance,not_stated,305
41,1st progression-free survival (PFS),Superiority hypothesis with p < 0.05,secondary,317
41,1st objective response rate (ORR),Superiority hypothesis with p < 0.01,secondary,316
41,1st disease control rate (DCR),Superiority hypothesis with p < 0.01,secondary,315
41,2nd progression-free survival (PFS),Superiority hypothesis with p < 0.05,secondary,321
41,2nd objective response rate (ORR),Superiority hypothesis with p < 0.01,secondary,320
41,2nd disease control rate (DCR),Superiority hypothesis with p < 0.05,secondary,319
41,"2nd PFS, Per protocol population",Superiority hypothesis with p < 0.05,exploratory,318
233,treatment-related adverse events (AEs),Absence of significant toxicities or treatment-related deaths and a manageable safety profile.,secondary,260
3742,best overall response (BOR) rate,">4 responses among 32 pts would be considered positive (BOR 5% vs 20%, 1-sided alpha 0.1, power 0.9)",primary,194
6108,dose-limiting toxicities (DLT),Establish the recommended Phase 2 dose (RP2D) using a 3+3 design.,not_stated,34
209,maximum-tolerated dose (MTD),Pts were treated according to a traditional 3+3 dose-escalation algorithm,primary,259
209,incidence of dose-limiting toxicities (DLTs),Pts were treated according to a traditional 3+3 dose-escalation algorithm,primary,258
2248,OS,Superiority based on p < 0.05,primary,113
2248,Perioperative morbidity,No significant difference in harm,secondary,114
1201,occurrence of adverse events and dose-limiting toxicities,"Occurrence of dose-limiting toxicities and specific adverse events (neurotoxicity, cytokine release syndrome > Grade 2, graft-versus-host disease).",primary,70
3925,Overall Response Rate (ORR),p < 0.05 for statistical significance,not_stated,208
3925,composite complete response (CRc),p < 0.05 for statistical significance,not_stated,210
3925,measurable residual disease (MRD) negativity,p < 0.05 for statistical significance,not_stated,211
3925,C0,p < 0.05 for statistical significance,exploratory,203
3925,Cmax,p < 0.05 for statistical significance,exploratory,204
3925,AUC(0–24),p < 0.05 for statistical significance,exploratory,202
3925,Neutropenic phase duration,p < 0.05 for statistical significance,not_stated,207
3925,Febrile neutropenia,p ≥ 0.05 for no significant difference in harm,exploratory,206
3925,Culture-positive infections,p ≥ 0.05 for no significant difference in harm,exploratory,205
3925,Treatment-related death,Absence of treatment-related death,exploratory,209
6221,rate of treatment success 8 weeks after the start of steroid administration,"The primary hypothesis was that a 3-week treatment would be non-inferior to a 6-week treatment, with a non-inferiority margin of 16 percentage points.",primary,45
6221,exploratory superiority analysis of the rate of treatment success,Superiority is met if p < 0.05.,exploratory,43
6221,quality of life,Superiority is met if the 95% CI for the difference excludes 0.,secondary,44
1292,safety,Establish a manageable safety profile.,primary,72
1292,dose-limiting toxicities (DLTs),Absence of dose-limiting toxicities at the tested dose levels.,primary,71
3359,objective response rate,H0 5%; Ha 25%; 5 pts with objective responses were needed to declare the combination worthy of further study.,co-primary,169
3359,rate of PFS at 6 months,H0 10%; Ha 30%; 6 pts progression-free and alive at 6 mos were needed to declare the combination worthy of further study.,co-primary,170
1598,safety and tolerability,Absence of dose-limiting toxicities.,primary,91
1598,CAR T expansion,Detection of A2B694 post-infusion in peripheral blood.,exploratory,90
1598,tumor infiltration,Detection of A2B694 in a tumor biopsy.,exploratory,92
3924,Dose-limiting toxicity (DLT),"Dose-limiting toxicity (DLT) and the maximum tolerated dose (MTD) were evaluated using accelerated titration and ""3+3"" escalation",primary,201
7,investigator-assessed rPFS (time from randomization to radiographic progression or death),"HR ≤0.64 to demonstrate efficacy (2-sided α, 0.025; power, 91%)",primary,327
7,time to symptomatic progression (TSP),p < 0.05 for superiority,secondary,329
7,overall survival (OS),p < 0.05 for superiority,secondary,328
4860,incidence and severity of irAEs,p < 0.05 for statistical significance,primary,302
4860,objective response rate (ORR) by RECIST v1.1,p < 0.05 for statistical significance,secondary,304
4860,analysis results of 16s rRNA and metabolomics detection of fecal samples,p < 0.05 for statistical significance,exploratory,301
4860,median onset time of irAEs,p < 0.05 for statistical significance,not_stated,303
92,centrally assessed residual cancer burden (RCB),Detect a RCB 0/I difference of 31% with 80% power at a two-sided alpha of 0.05.,primary,164
2345,objective response rate (ORR),Increase the objective response rate (ORR) from 50% to 68%; met if a total of 23 patients achieve objective responses based on Simon's minimax two-stage design.,primary,124
5023,rate of grade (gr) 3-5 irAEs,"The observed rate of grade 3-5 irAEs is significantly different from the known irAE rate of Nivo, Rela, and Ipi, tested with a 2-sided alpha = 0.05.",co-primary,250
5023,Circulating IL-6 signaling mediators,A significant change from baseline (P < 0.05).,exploratory,249
5052,rate of pts maintaining sonidegib 12 months after study enrolment,The rate of patients maintaining sonidegib at 12 months should be at least 60% (H1) versus a null hypothesis of 31% (H0).,primary,253
1633,disease control (DC) in BC cohort,"If ≥7 of 28 pts had DC, the null DC rate was rejected.",primary,97
1633,disease control (DC) in OC cohort,"If ≥7 of 28 pts had DC, the null DC rate was rejected.",primary,98
4112,PK exposure,No significant difference in PK exposure between monotherapy and combination therapy.,exploratory,218
4112,ADA incidence rate,No significant difference in ADA incidence rate between monotherapy and combination therapy.,exploratory,217
15,overall survival (OS),p < 0.05 for statistical significance,secondary,334
15,Grade 3/4 hematological toxicities,p < 0.05 for statistical significance,secondary,331
15,Grade 3/4 gastrointestinal toxicities,p < 0.05 for statistical significance,secondary,330
15,global health status,p < 0.05 for statistical significance,secondary,333
15,erectile dysfunction-related bother,p < 0.05 for statistical significance,secondary,332
3614,disease control (DC),"If ≥7 of 28 pts had DC, the null DC rate was rejected.",primary,286
291,progression-free survival (PFS),targeting an improvement from 8 to 12 months,primary,14
291,correlations between intrinsic subtype and treatment efficacy,Test for significant correlation between intrinsic subtype and efficacy.,exploratory,13
107,pCR rate in patients with TASOR2 or MST1R mutation,p < 0.05 for statistical significance,exploratory,173
107,pCR rate in patients with CCND1 amplification,p < 0.05 for statistical significance,exploratory,172
5216,Safety,Assess the incidence and severity of dose-limiting toxicities (DLTs) and adverse events (AEs).,primary,3
5216,Recommended phase 2 dose (RP2D),Confirm the recommended phase 2 dose (RP2D) based on dose-limiting toxicities.,primary,2
5216,Best Overall Response rate,Achieve a pre-specified rate of Best Overall Response.,secondary,1
4727,changes in circulating tumor DNA (ctDNA) and their correlation with clinical outcomes,p < 0.05,exploratory,240
5227,event-free survival time (EFS),Pr[true hazard ratio > 1 | data],primary,5
5227,overall survival time (OS),Pr[true hazard ratio > 1 | data],secondary,6
1288,safety,Absence of treatment-related serious or grade > 3 adverse events.,primary,76
19,ORR assessed by BICR,p < 0.05 for statistical significance,primary,343
19,PFS assessed by BICR,p < 0.05 for statistical significance and HR CI < 1,primary,346
19,OS,HR CI must exclude 1 for statistical significance,primary,344
19,OS (supplementary analysis),HR CI must exclude 1 for statistical significance,exploratory,345
1052,Overall survival (OS) after concurrent (conc) TMZ in the intent-to-treat population,"Superiority of concurrent TMZ vs. no concurrent TMZ, inferred as requiring p < 0.05 and HR < 1 with CI excluding 1.",not_stated,58
1052,Overall survival (OS) after adjuvant (adj) TMZ in the intent-to-treat population,"Superiority of adjuvant TMZ vs. no adjuvant TMZ, inferred as requiring p < 0.05 and HR < 1 with CI excluding 1.",not_stated,57
1052,OS for concTMZ in patients with IDHmt tumors,"Superiority of concurrent TMZ vs. no concurrent TMZ in the IDHmt subgroup, inferred as requiring p < 0.05 and HR < 1 with CI excluding 1.",not_stated,56
1052,OS for adjTMZ in patients with IDHmt tumors,"Superiority of adjuvant TMZ vs. no adjuvant TMZ in the IDHmt subgroup, inferred as requiring p < 0.05 and HR < 1 with CI excluding 1.",not_stated,55
1052,Benefit of concTMZ in IDHmt glioma patients that also received adjTMZ,"Superiority of concurrent TMZ vs. no concurrent TMZ in the IDHmt + adjuvant TMZ subgroup, inferred as requiring p < 0.05 and HR < 1 with CI excluding 1.",not_stated,53
1052,Median OS in patients treated with adjTMZ,"Statistical significance of the median OS estimate, inferred as requiring p < 0.05.",not_stated,54
4638,Progression-Free Survival (PFS) in patients with ≥30% intense and complete CEA staining in tumor cells and no brain metastases,p < 0.05 for superiority,not_stated,237
4638,Overall Survival (OS) in patients with ≥30% intense and complete CEA staining in tumor cells and no brain metastases,p < 0.05 for superiority,not_stated,236
1318,objective response rate,p < 0.05 for statistical significance,primary,82
1318,toxicity,P > 0.05 for no significant difference,secondary,83
1318,PFS,p < 0.05 for statistical significance,secondary,78
1318,OS,p < 0.05 for statistical significance,secondary,77
1318,complete response (CR) rates,p < 0.05 for statistical significance,not_stated,80
1318,double positive T lymphocyte subset percent,p < 0.05 for statistical significance,exploratory,81
1318,absolute CD4+T lymphocyte count,p < 0.05 for statistical significance,exploratory,79
46,Independent Review Committee (IRC)-assessed PFS,"Detect a hazard ratio of 0.58, at a two-sided alpha level of 5%.",primary,309
46,objective response rate (ORR),p < 0.05,secondary,310
3632,R0/R1 resection rate,Improvement over historical R0/R1 resection rate of 5%,primary,178
3632,Surgical morbidity score,p < 0.05 for superiority (improvement),not_stated,179
3632,2-year OS by pathologic response status,p < 0.05 for superiority,exploratory,177
48,ORR per RECIST v1.1 by investigator,Superiority based on Cochran-Mantel-Haenszel test for rate difference.,primary,323
48,DCR,Superiority based on Cochran-Mantel-Haenszel test for rate difference.,not_stated,322
48,mPFS,p < 0.05 for superiority,not_stated,324
3123,Recommended phase 2 dose (RP2D),dose escalation/de-escalation of both agents by up to 2 dose levels based on a 3+3 design to define the recommended phase 2 dose (RP2D),primary,150
3123,Safety,Assess preliminary safety,secondary,151
6196,nausea prevention,Superiority is met if p < 0.05,primary,40
6196,no emesis,Superiority is met if p < 0.05,secondary,41
6196,no rescue medications,Superiority is met if p < 0.05,secondary,42
6196,Total number of vomiting episodes >15 times,Superiority is met if p < 0.05,not_stated,39
6196,Mean anxiety score,Superiority is met if p < 0.05,not_stated,36
6196,Mean depression score,Superiority is met if p < 0.05,not_stated,37
6196,Sleep hours/day,Superiority is met if p < 0.05,not_stated,38
6196,Mean EORTC GHS QOL score,Superiority is met if p < 0.05,not_stated,35
6202,no CIT-induced dose modification of any myelosuppressive agent in either the second or third chemotherapy cycle,Superiority vs placebo based on p-value < alpha,primary,47
6202,Median Plt nadirs,Superiority vs placebo based on p-value < alpha,not_stated,46
6202,time to first Plt response,Superiority vs placebo based on p-value < alpha,not_stated,48
2877,disease-free survival (DFS),"Superiority of pembrolizumab over placebo, defined by a Hazard Ratio (HR) with a 95% confidence interval upper bound of <1.0.",primary,130
2877,overall survival (OS),"Superiority of pembrolizumab over placebo, defined by a Hazard Ratio (HR) with a 95% confidence interval upper bound of <1.0.",key secondary,131
2877,serious treatment-related AEs,Absence of new safety signals.,not_stated,132
1088,safety,"Adverse events within 28 days of first dose and at least possibly related to B7H3-CART were considered dose-limiting toxicities (DLTs) if meeting additional criteria: any grade 5 toxicity, grade 4 cytokine release syndrome, neutropenia, or thrombocytopenia lasting > 14 days, or any non-hematologic grade 3 toxicity lasting > 72 hours. Neurotoxicity was considered a DLT if grade 4 for > 96 hours or new-onset grade 3 for > 28 days.",primary,61
1088,manufacturing feasibility,Successful manufacturing of B7H3-CART for enrolled patients.,primary,60
2882,cCR rate,"H0≤30%, H1≥45%; for 2-stage design, ≥7 cCR needed in first stage of 23 pts.",primary,136
2882,complete pathologic (ypT0) responses by Genomic Subtyping Classifier (GSC) groups,p < 0.05 for statistical significance,exploratory,137
2882,association of stromal signature with non-ypT0 response,p < 0.05 for statistical significance,exploratory,135
2882,association of Trop2 gene expression with ypT0 response,p < 0.05 for statistical significance,exploratory,134
2882,association of TOP1 gene expression with ypT0 response,p < 0.05 for statistical significance,exploratory,133
2120,decrease in the number of ctDNA mutations with therapeutic response,p < 0.05,exploratory,274
2120,decrease in ctDNA mutation abundance with therapeutic response,p < 0.05,exploratory,272
2120,decrease in ctDNA mutation level with therapeutic response,p < 0.05,exploratory,273
73,disease free survival (DFS),Superiority is met if the upper bound of the 95% CI for the Hazard Ratio is less than 1.0.,primary,162
73,overall survival (OS),Superiority is met if the upper bound of the 95% CI for the Hazard Ratio is less than 1.0.,secondary,163
73,breast cancer-free interval (BCFI),Superiority is met if the upper bound of the 95% CI for the Hazard Ratio is less than 1.0.,post-hoc,161
2892,overall survival (OS),Inferred superiority hypothesis (HR < 1),primary,128
2892,overall survival (OS) in ITT,Inferred superiority hypothesis (HR < 1),secondary,129
2892,independent radiology review committee (IRRC)-assessed objective response rate (ORR),Inferred superiority hypothesis (higher ORR is better),primary,127
2892,Safety,No new safety signals,not_stated,125
2892,duration of response (DOR),Inferred superiority hypothesis (longer DOR is better),not_stated,126
3668,2-year overall survival (OS),p < 0.05 for statistical significance,primary,186
3668,2-year progression-free survival (PFS),p < 0.05 for statistical significance,not_stated,187
3679,Complete response (CR) rate after neoadjuvant treatment,Superiority based on p < 0.05,secondary,188
3679,Overall response rate (ORR) after neoadjuvant treatment,Superiority based on p < 0.05,not_stated,191
3679,Grade 3-4 acute treatment-related adverse events (trAEs),No significant difference in harm (p >= 0.05),not_stated,189
3679,Immune-related AEs (irAEs),No significant difference in harm (p >= 0.05),not_stated,190
5217,safety profile,"DLTs included Grade 3 diarrhoea, enterocolitis, ileus or oral mucositis persisting > 3 days; Grade 4 diarrhoea; neutropenia or thrombocytopenia delaying treatment > 7 days; Grade 3/4 toxicities resulting in treatment discontinuation, or any Grade 5 toxicity (death) related to trial treatment.",primary,12
5217,highest tested dose (HTD),Determine the HTD based on the dose escalation schema ('rolling six design') and observed DLTs.,primary,10
5217,recommended phase 2 dose (RP2D),Determine the RP2D based on the safety profile and DLTs observed during dose escalation using a rolling six design.,primary,11
390,Overall Survival (OS),"Superiority of iTNBC vs cTNBC, defined as p < 0.05 or HR with 95% CI upper bound < 1.",not_stated,26
390,Overall Response Rate (ORR),"Superiority of iTNBC vs cTNBC, defined as p < 0.05.",not_stated,25
390,Progression-Free Survival (PFS),"Superiority of iTNBC vs cTNBC, defined as HR with 95% CI upper bound < 1.",not_stated,28
390,PD-L1 expression change,"Significant change from baseline, defined as p < 0.05.",exploratory,27
390,Association of LNR with OS,"Significant correlation, defined as p < 0.05.",exploratory,23
390,Association of MLR with OS,"Significant correlation, defined as p < 0.05.",exploratory,24
6278,"quality of life, assessed using the EORTC QLQ-C30 and its specific module for lung cancer (QLQ-LC13)",p < alpha for superiority,secondary,51
6278,insomnia,p < 0.05 for superiority,secondary,50
6278,dyspnea,p < 0.05 for superiority,secondary,49
2958,best overall objective response rate (ORR; RECIST v1.1),"If ≥4 of the first 19 patients (Stage 1) achieved an objective response (confirmed partial or complete response), then recruitment would continue through Stage 2.",primary,145
2958,safety and tolerability (CTCAEv5),No new or unexpected safety signals.,secondary,146
1941,pCR rate in mITT population,p < 0.05 for superiority,primary,111
1941,major pathological response (MPR) rate,p < 0.05 for superiority,secondary,110
1941,downstaging (ypStage 0 to 1),p < 0.05 for superiority,not_stated,109
1941,pCR rates in PP analysis,p < 0.05 for superiority,not_stated,112
5020,safety (treatment-emergent adverse events [TEAEs]: AEs ≤30 d after OBX-115 infusion),Absence of dose-limiting toxicity (DLT),primary,251
5020,tolerability in escalating dose levels of OBX-115 and ACZ to establish a recommended phase 2 dose (RP2D),Establish a recommended phase 2 dose (RP2D),primary,252
6056,recommended phase 2 dose (RP2D),Establish the RP2D using a i3+3 dose escalation design.,primary,33
6056,Safety and Tolerability,Assess safety and tolerability to determine DLTs and RP2D.,secondary,32
6067,Progression-free survival (PFS),Superiority based on Log Rank test p-value < 0.05.,primary,31
6067,PFS for patients stratified at ≤ 3 prior lines,Superiority based on p-value < 0.05.,not_stated,30
4275,"minimal residual disease (MRD) negativity (NGF, 10-5) at the end of consolidation",MRD-neg rate ≤50%,primary,220
4275,PFS benefit of reaching and remaining in MRD-neg state,Superiority based on CI for HR excluding 1,exploratory,219
2744,Safety,Evaluate safety and tolerability in a 3+3 dose-escalation design.,primary,284
2744,Tolerability,Evaluate safety and tolerability in a 3+3 dose-escalation design.,primary,285
2744,Dose-Limiting Toxicity (DLT),Observation for DLTs during a 28-day period.,primary,283
1222,safety and tolerability of ICP-B05,Assess safety and tolerability of ICP-B05.,primary,67
1222,PD,Demonstrate a significant reduction of CCR8-expressing cells from baseline.,secondary,66
1274,Determination of the Part 2 dose,The Part 1 dose escalation was guided by a mTPI design to determine the Part 2 dose of Q702 in combination with pembrolizumab.,primary,73
1274,Safety profile,Assess safety and tolerability.,not_stated,75
1274,Overall response assessment (RECIST 1.1),Assess preliminary anti-tumor activity.,not_stated,74
